SYNTHBODYTM
pipeline
| Program | Class | Indication | Target | Discovery | Lead Opt. | IND Enabling | ||
|---|---|---|---|---|---|---|---|---|
| Oncology | ||||||||
| SDL-001 | ADC | Myeloma, AI | CD38, BCMA, GPRC5D |
▶
|
||||
| SDL-002 | ADC | NHL, AI | NOT DISCLOSED |
▶
|
||||
| SDL-003 | ADC | Solid Tumor | NOT DISCLOSED |
▶
|
||||
| Non-Oncology | ||||||||
| STN-001 | Metabolism | Obesity | NOT DISCLOSED |
▶
|
||||
| STN-002 | Metabolism | Obesity, Addiction | NOT DISCLOSED |
▶
|
||||
| STN-003 | Metabolism | Obesity, Muscle Sparing | NOT DISCLOSED |
▶
|
||||
| SDL represent SYNTHBODYTM therapies for Oncology; STN represent SYNTHBODYTM therapies for Non-Oncology | ||||||||
.svg)